Cytopathic viruses for therapy and prophylaxis of neoplasia

Details Cytopathic viruses for therapy and prophylaxis of neoplasia Cytopathic viruses for therapy and prophylaxis of neoplasia

1995-06-07

1998-12-08

Degen, Nancy

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

4352351, 4353701, 435325, 435375, 536 231, 536 241, C12N 510, C12N 701, C07H 2104, A61K 3170

Patent

active

058469451

ABSTRACT:
Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

REFERENCES:
Orkin "Report & Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy", 1995.
Shepherd et al., J. of Virology, 67(5):2944-2949 (1993).
Chang et al., British J. Cancer, 68(4):653-661 (1993).
Subramanian et al., Cell Growth & Differentiation, 6:131-137 (1995).
Barker et al, Virology, 156:107-121 (1989).
Barbeau et al., Oncogene, 9(2):359-373 (1994).
Phelps et al., J. of Virology, 66(4):2418-2427 (1992).
Brokaw et al., Virology, 205:603-607 (1994).
Shingu et al., J. Gen Virol., 72:2031-2034 (1991).
Martuza et al., Science, 252:854-856 (1991).
Horwitz, "Adenoviral Diseases" in Virology, Fields et al, eds., Raven Press (New York), 477-495 (1985).
Whyte et al., Cell, 56:67-75 (1989).
Cote et al, Cancer Research, 51:5410-5436 (1991).
Maxwell et al, Cancer Research, 46:4660-4664 (1986).
Brody et al, Am. Rev. Respir. Dis., 145:425A (1992).
Graham et al, Methods in Molecular Biology, 7:109-128 (1991).
Smith et al., Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix, Cancer, vol. 9, pp. 1211-1218 (1956).
Newman et al., Virus Treatment in Advanced Cancer, Cancer, vol. 7, pp. 106-118, (1954).
Alice E. Moore, Effects of Viruses on Tumors, Ann Rev Microbiol, vol. 8, pp. 393-410 (1954).
F.L. Graham, Transformation by and Oncogenicity of Human Adenoviruses, The Adenoviruses, Chapter 9, pp. 339-383 (1984).
Bjorn et al., Selective Elimination of Breast Cancer Cells from Human Bone Marrow Using an Antibody-Pseudomonas, Cancer Research, vol. 50, pp. 5992-5996, (1990).
Crook et al., Degradation of p53 Can Be Targeted by HPV E6 Sequences Distinct from Those Required for p53 Binding and Trans-activation. Cell, vol. 67, pp. 547-556 (1991).
Mietz et al., The Transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO, vol. 11, pp. 5013-5020 (1992).

Affiliated with

Also associated with

Rating

Cytopathic viruses for therapy and prophylaxis of neoplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytopathic viruses for therapy and prophylaxis of neoplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytopathic viruses for therapy and prophylaxis of neoplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-177340